Hepatitis C News and Research

Latest Hepatitis C News and Research

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Palatin Technologies, Inc., a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.

13 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load in people infected with the virus.

13 May 2010

Medco announces new $3 billion share repurchase program

Medco Health Solutions, Inc. today announced that its Board of Directors has unanimously approved a new $3 billion share repurchase program.

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Achillion Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

NanoViricides, Inc., announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering. The registered shelf offering became effective on April 29, 2010.

12 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.

12 May 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Today, the biotech-vaccine company Intercell AG announced its financial results for Q1 and presented an update on the Company's development programs.

11 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Lawsuit over hepatitis C infections contracted from Doctor

Nearly 30 women got infected with Hepatitis C virus due to a breach in infection prevention protocols by an anaesthetist at a late-term abortion clinic. The incidents occurred at the Croydon Day Surgery in Melbourne's eastern suburbs during an 18-month period when James Latham Peters was working as an anaesthetist. The issue had come to light in the last few weeks. Now a multi million dollar lawsuit against the Medical Practitioners Board of Victoria on behalf of the allegedly infected women is being planned.

9 May 2010

Nokia launches Ovi Life Tools in China

Nokia today announced the launch of Ovi Life Tools in China. Designed for the emerging markets, Ovi Life Tools offers a wide range of information services covering healthcare, agriculture, education and entertainment.

7 May 2010

New CD4 test kit can improve quality of life for HIV and AIDS patients

The use of rapid point-of-care diagnostic tests for the measurement of CD4 T-cells, a marker of the immune system will be an important factor in improving the lives of people living with HIV and AIDS especially in developing and resource-poor countries.

7 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2010.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Chimerix commences first-in-human study of CMX157 for HIV

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

Medco announces new $3 billion share repurchase program

Data on Qnexa to be presented at World Congress on CODHy in Prague

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

Increased IR associated with HCC development in chronic HCV-infected patients

Sex can affect frequency and severity of adverse effects of vaccination

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

Merck hosts R&D and Business Briefing

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Lawsuit over hepatitis C infections contracted from Doctor

Nokia launches Ovi Life Tools in China

New CD4 test kit can improve quality of life for HIV and AIDS patients

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in